Undisclosed Therapeutic Program(s)

About HeartcoR Solutions

HeartcoR Solutions is a San Francisco-based biotech company developing integrated cardiovascular and digital health solutions. The company is in a critical transition phase, advancing programs through late-stage preclinical or early clinical development as indicated by its preparation for IND filings and post-market surveillance activities. As a private, pre-revenue entity, its success hinges on successful clinical translation, regulatory navigation, and securing strategic partnerships or additional funding to bring its pipeline to market. The company targets a significant market opportunity in cardiovascular disease, one of the world's leading causes of mortality and healthcare expenditure.

About Bright Cell

Bright Cell is a private, early-stage biotech firm founded in 2018 and headquartered in Boston, with an operational address in Irvine, California. The company is developing a pipeline of stem cell-based therapeutic candidates, some of which are in US FDA-regulated clinical trials, while also offering commercial services in R&D, CDMO, and cell banking. Its business model combines therapeutic development with service revenue, positioning it in the high-growth regenerative medicine market, though it faces significant risks common to pre-revenue biotech ventures, including clinical trial outcomes and funding needs.

About Tradewind Bioscience

Tradewind Bioscience is a preclinical biotech targeting aggressive, metastatic cancers through an integrated approach of novel therapeutics and companion diagnostics. Founded in 2018, the company leverages proprietary science and assays from its founders to develop biomarker-driven treatments. As a private, pre-revenue entity, it operates with a science-driven drug development model aimed at identifying patients most likely to benefit from its therapies.

Therapeutic Areas

Other Cardiovascular Disease Drugs